How effective is ensifentrine-Ohtuvayre in treating COPD?

Ensifentine Inhalation Suspension Solution (Ensifentrine)-Ohtuvayre is an innovative dual-mechanism inhaled drug designed to provide patients with chronic obstructive pulmonary disease (COPD) with more comprehensive treatment options. The drug achieves the dual effects of bronchodilation and anti-inflammatory effects by simultaneously inhibiting phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4). PDE3 inhibition can relax bronchial smooth muscles and improve airflow restriction, thereby alleviating patients' symptoms of dyspnea and chest tightness; while PDE4 inhibition can reduce the release of inflammatory mediators and help control airway inflammatory responses.

Clinical studies have shown that exefantine can quickly improve lung function indicators after inhalation, and has a certain auxiliary effect in relieving acute exacerbations of COPD. At the same time, the drug's dual mechanism of action provides a potential alternative to traditional single-acting bronchodilators and inhaled anti-inflammatory drugs. During the course of use, patients' FEV1 and symptom scores showed a considerable improvement trend, and their daily activities and quality of life also improved. Exefentine has potential advantages in symptom control and quality of life improvement compared with conventional medications.

In addition, exefantine is administered by inhalation, which facilitates patient self-management, and the inhaled drug can directly act on the lungs, increasing the local concentration of the drug while reducing the risk of systemic adverse reactions. This administration feature makes it potentially useful in long-term maintenance treatment of COPD. However, it has not yet been fully marketed in China, and its long-term efficacy and safety still require further follow-up and practical verification. Exefantine provides a new treatment idea for patients with COPD, especially those who have poor response to traditional treatments or who require dual mechanism of action intervention. Its innovative mechanism and convenience of inhalation have certain development prospects in future clinical applications.

Reference materials:https://www.drugs.com/monograph/ensifentrine.html